Use of mycophenolate mofetil in immunosuppressive protocols in elderly renal transplant recipients [1]

Transplantation

Volumn 76, Issue 3, 2003, Pages 619-

  Johnson, David W ^a   Nicol, David L ^b   Preston, John M ^b   Brown, Allison M ^b   Hawley, Carmel M ^b   Campbell, Scott B ^b   Wall, Darryl ^b   Griffin, Anthony D ^b   Isbel, Nicole M ^b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

AGE; AGED; BODY MASS; DIABETES MELLITUS; DRUG USE; GENDER; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIA; ISCHEMIC HEART DISEASE; KIDNEY TRANSPLANTATION; LETTER; LIVING DONOR; PRIORITY JOURNAL; RACE; SENESCENCE; SMOKING;

EID: 0042967921     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000074314.46438.25     Document Type: Letter

References (3)

1. Johnson DW, Nicol DL, Purdie DM, et al. Is mycophenolate mofetil less safe than azathioprine in elderly renal transplant recipients? Transplantation. 2002; 73: 1158.
2. Meier-Kriesche HU, Friedman G, Jacobs M, et al. Infectious complications in geriatric renal transplant patients: comparison of two immunosuppressive protocols. Transplantation 1999; 68: 1496.
3. Sureshkumar KK, Nghiem DD. Use of mycophenolate mofetil in immunosuppressive protocols in elderly renal transplant recipients. Transplantation 2003; 76: 441.